Results 171 to 180 of about 43,079 (212)

Comparison of changes in blood cells and hemostatic biomarkers in mouse xenograft models of acute myeloid leukemia and acute promyelocytic leukemia. [PDF]

Res Pract Thromb Haemost
Archibald SJ, Sachetto ATA, Zhu X, Gangaraju R, Mackman N, Hisada Y.   +5 more
europepmc   +1 more source

Pro-Apoptotic and Cytotoxic Effects of Melittin on HL-60 Acute Promyelocytic Leukemia Cells: Implications for Retinoid-Independent Therapy. [PDF]

Molecules
Stela M, Ceremuga M, Cichon N, Poplawski T, Podogrocki M, Gorniak L, Bijak M.   +6 more
europepmc   +1 more source

Acute Promyelocytic Leukemia Presenting as Spontaneous Abortion Amidst Tropical Fever Season: A Diagnostic Challenge. [PDF]

Cureus
Rathod A, Gupta M, Palta A.
europepmc   +1 more source

Severe Gout During Arsenic Therapy: Insights on Oxidative Stress and Interleukin-1β in Gout. [PDF]

ACR Open Rheumatol
Hamilton J, Alexander A.
europepmc   +1 more source

JC Virus Agnogene Regulates Histone-Modifying Enzymes via PML-NBs: Transcriptomics in VLP-Expressing Cells. [PDF]

Viruses
Shishido-Hara Y, Yaoi T.
europepmc   +1 more source

Association between leukemic immunophenotype and overall survival in patients with acute promyelocytic leukemia: a retrospective cohort study. [PDF]

Front Cell Dev Biol
Zha X, Ma L, Yue Y, Wei X, Sun B, Wang W.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Activation of a promyelocytic leukemia–tumor protein 53 axis underlies acute promyelocytic leukemia cure

Nature Medicine, 2014
Acute promyelocytic leukemia (APL) is driven by the promyelocytic leukemia (PML)-retinoic acid receptor-α (PML-RARA) fusion protein, which interferes with nuclear receptor signaling and PML nuclear body (NB) assembly. APL is the only malignancy definitively cured by targeted therapies: retinoic acid (RA) and/or arsenic trioxide, which both trigger PML ...
Julien Ablain, Kim Rice, Hassane Soilihi, Aurxe9lien de Reynies, Saverio Minucci, Hugues de Thxe9   +5 more
openaire   +4 more sources

Promyelocytic leukemia protein: an atherosclerosis suppressor protein?

Clinical Science, 2021
Abstract As many as 70% of cells in atherosclerotic plaque are vascular smooth muscle cell (VSMC) in origin, and pathways and proteins which regulate VSMC migration, proliferation, and phenotype modulation represent novel targets for rational drug design to reduce atherosclerotic vascular disease.
Cali B, Corbett, Amanda K, St Paul, Michael V, Autieri   +2 more
openaire   +2 more sources

ImageStream promyelocytic leukemia protein immunolocalization: In search of promyelocytic leukemia cells

Cytometry Part A, 2012
AbstractAcute promyelocytic leukemia (APL) is a hematological emergency in which a rapid diagnosis is essential for early administration of appropriate therapy, including all‐trans retinoic acid before the onset of fatal coagulopathy. Currently, the following methodologies are widely used for rapid initial diagnosis of APL: 1) identification of ...
Mirabelli P., Scalia G., Pascariello C., D'Alessio F., Mariotti E., DI NOTO, ROSA, George T. C., Kong R., Venkatachalam V., Basiji D., DEL VECCHIO, LUIGI   +10 more
openaire   +3 more sources